Investigate / AFL
Understand AFLAC INC
Can the supplemental insurance model keep delivering through changes in yen/dollar conditions, interest rates and investment credit quality?
Snapshot reviewed 2026-10-02. Source published 2026-08-07. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / AFL
Ask better questions. Keep the evidence.
Explore the available sources for AFLAC INC, then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
Customers pay for supplemental health and life insurance; when a policyholder or insured gets sick or hurt, the Company pays cash benefits on eligible claims.
Latticework interpretation
What could support the case?
If the strategy of selling supplemental health products through agents, brokers, partners or directly continues to reach customers where they prefer to buy, distribution breadth could support the business.
Latticework interpretation
What could break the case?
If continued high interest rates and economic weakness persist, investments such as commercial real estate and highly leveraged companies may experience higher credit losses, downgrades or defaults, which could pressure results.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Customers pay for supplemental health and life insurance; when a policyholder or insured gets sick or hurt, the Company pays cash benefits on eligible claims.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $4,117m | $4,160m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $825m | $599m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $1,080m | $988m |
3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If the strategy of selling supplemental health products through agents, brokers, partners or directly continues to reach customers where they prefer to buy, distribution breadth could support the business.
Supporting filing ↗The strongest caution
If continued high interest rates and economic weakness persist, investments such as commercial real estate and highly leveraged companies may experience higher credit losses, downgrades or defaults, which could pressure results.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How exposed is the business to Japan and the yen?
Starting evidence: The Company lists concentration of business in Japan as a factor that could cause actual results to differ materially.
Investigate next: Review segment disclosures and currency sensitivity discussion to see how yen/dollar moves could affect reported results.
Read the supporting filing ↗How large are hedging costs on yen-based investing?
Starting evidence: The continuing difference between U.S. dollar and yen interest rates contributes to costs of hedging foreign currency risk on dollar investments held by Aflac Japan.
Investigate next: Examine hedging disclosures and how the rate gap has affected net investment income and capital position.
Read the supporting filing ↗Are pricing and reserving assumptions holding up?
Starting evidence: The Company flags deviations in actual experience from pricing and reserving assumptions as a factor that could cause results to differ materially.
Investigate next: Compare actual claims experience with assumptions in benefit reserve disclosures and look for assumption updates.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.